Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index

被引：81

作者：

Buti, Sebastiano ^{[1
]}

Bersanelli, Melissa ^{[1
,2
]}

Perrone, Fabiana ^{[1
]}

Tiseo, Marcello ^{[1
,2
]}

Tucci, Marco ^{[3
,4
]}

Adamo, Vincenzo ^{[5
,6
]}

Stucci, Luigia S. ^{[3
]}

Russo, Alessandro ^{[5
,6
]}

Tanda, Enrica T. ^{[7
]}

Spagnolo, Francesco ^{[7
]}

Rastelli, Francesca ^{[9
]}

Pergolesi, Federica ^{[8
]}

Santini, Daniele ^{[9
]}

Russano, Marco ^{[9
]}

Anesi, Cecilia ^{[9
]}

Giusti, Raffaele ^{[10
]}

Filetti, Marco ^{[10
]}

Marchetti, Paolo ^{[10
,11
,12
]}

Botticelli, Andrea ^{[11
,12
]}

Gelibter, Alain ^{[12
]}

Occhipinti, Mario Alberto ^{[13
]}

Ferrari, Marco ^{[13
]}

Vitale, Maria Giuseppa ^{[14
]}

Nicolardi, Linda ^{[15
]}

Chiari, Rita ^{[15
]}

Rijavec, Erika ^{[16
]}

Nigro, Olga ^{[17
]}

Tuzi, Alessandro ^{[17
]}

De Tursi, Michele ^{[18
]}

Di Marino, Pietro ^{[19
]}

Conforti, Fabio ^{[20
]}

Queirolo, Paola ^{[20
]}

Bracarda, Sergio ^{[21
]}

Macrini, Serena ^{[21
]}

Gori, Stefania ^{[22
]}

Zoratto, Federica ^{[23
]}

Veltri, Enzo ^{[23
]}

Di Cocco, Barbara ^{[23
]}

Mallardo, Domenico ^{[24
]}

Vitale, Maria Grazia ^{[24
]}

Santoni, Matteo ^{[25
]}

Patruno, Leonardo ^{[26
,27
]}

Porzio, Giampiero ^{[26
]}

Ficorella, Corrado ^{[26
,27
]}

Pinato, David J. ^{[28
]}

Ascierto, Paolo A. ^{[24
]}

Cortellini, Alessio ^{[26
,27
]}

机构：

[1] Univ Hosp Parma, Med Oncol Unit, Parma, Italy

[2] Univ Parma, Dept Med & Surg, Parma, Italy

[3] Univ Bari, Dept Biomed Sci & Human Oncol, Med Oncol Unit, Bari, Italy

[4] Tumori Inst IRCCS Giovanni Paolo II, Natl Canc Res Ctr, Bari, Italy

[5] Univ Messina, AO Papardo, Med Oncol, Messina, Italy

[6] Univ Messina, Dept Human Pathol, Messina, Italy

[7] IRCCS Osped Policlin San Martino, Genoa, Italy

[8] Fermo Area Vasta 4, Med Oncol, Fermo, Italy

[9] Campus Biomed Univ, Med Oncol, Rome, Italy

[10] St Andrea Hosp Rome, Med Oncol Unit, Rome, Italy

[11] Sapienza Univ Rome, Dept Clin & Mol Med, Rome, Italy

[12] Sapienza Univ Rome, Policlin Umberto I, Med Oncol B, Rome, Italy

[13] Azienda Osped Univ Pisana, Med Oncol, Pisa, Italy

[14] Univ Hosp Modena, Med Oncol, Modena, Italy

[15] UOC Oncol Padova Sud AULSS6 Euganea, Padua, Italy

[16] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Med Oncol Unit, Milan, Italy

[17] Osped Circolo & Fdn Macchi, ASST Sette Laghi, Med Oncol, Varese, Italy

[18] Univ G DAnnunzio, Dept Med Oral & Biotechnol Sci, Chieti, Italy

[19] SS Annuniata Hosp, Clin Oncol Unit, Chieti, Italy

[20] European Inst Oncol IRCCS, Div Med Oncol Melanoma Sarcoma & Rare Tumors, IEO, Milan, Italy

[21] Azienda Osped S Maria, SC Med Oncol, Terni, Italy

[22] IRCCS Osped Sacro Cuore Don Calabria, Oncol Unit, Negrar, VR, Italy

[23] Santa Maria Goretti Hosp, Med Oncol, Latina, Italy

[24] Ist Nazl Tumori IRCCS Fdn G Pascale, Melanoma Canc Immunotherapy & Dev Therapeut Unit, Naples, Italy

[25] Macerata Hosp, Dept Oncol, Macerata, Italy

[26] St Salvatore Hosp, Med Oncol Unit, Laquila, Italy

[27] Univ Aquila, Dept Biotechnol & Appl Clin Sci, Laquila, Italy

[28] Imperial Coll London, Hammersmith Hosp, Fac Med, Dept Surg & Canc, London, England

来源：

EUROPEAN JOURNAL OF CANCER | 2021年 / 142卷

关键词：

Concomitant medications; Drugs; Immunotherapy; Corticosteroids; Proton-pump inhibitors; Antibiotics; Immune checkpoint inhibitors; Cancer patients; Score; Index; Prognostic; PROTON PUMP INHIBITORS; GUT MICROBIOME; ANTIBIOTICS; EFFICACY; IMPACT; PD-1;

D O I：

10.1016/j.ejca.2020.09.033

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Concomitant medications are known to impact on clinical outcomes of patients treated with immune checkpoint inhibitors (ICIs). We aimed weighing the role of different concomitant baseline medications to create a drug-based prognostic score. Methods: We evaluated concomitant baseline medications at immunotherapy initiation for their impact on objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) in a single-institution cohort of patients with advanced cancer treated with ICIs (training cohort, N = 217), and a drug-based prognostic score with the drugs resulting significantly impacting the OS was computed. Secondly, we externally validated the score in a large multicenter external cohort (n = 1012). Results: In the training cohort (n=217), the median age was 69 years (range: 32-89), and the primary tumours were nonesmall-cell lung cancer (70%), melanoma (14.7%), renal cell carcinoma (9.2%) and others (6%). Among baseline medications, corticosteroids (hazard ratio [HR] = 2.3; 95% confidence interval [ CI]: 1.60-3.30), systemic antibiotics (HR = 2.07; 95% CI: 1.31-3.25) and proton-pump inhibitors (PPIs) (HR = 1.57; 95% CI: 1.13-2.18) were significantly associated with OS. The prognostic score was calculated using these three drug classes, defining good, intermediate and poor prognosis patients. Within the training cohort, OS (p < 0.0001), PFS (p < 0.0001) and ORR (p = 0.0297) were significantly distinguished by the score stratification. The prognostic value of the score was also demonstrated in terms of OS (p < 0.0001), PFS (p < 0.0001) and ORR (p = 0.0006) within the external cohort. Conclusion: Cumulative exposure to corticosteroids, antibiotics and PPIs (three likely microbiota-modulating drugs) leads to progressively worse outcomes after ICI therapy. We propose a simple score that can help stratifying patients in routine practice and clinical trials of ICIs. (C) 2020 Elsevier Ltd. All rights reserved.

引用

页码：18 / 28

页数：11

共 50 条

[1] Association of the pretreatment lung immune prognostic index with survival outcomes in advanced gastric cancer patients treated with immune checkpoint inhibitors
Hou, Baicun
Wang, Peng
Liu, Tingting
Chen, Shixue
Li, Tao
Zhang, Sujie
Tao, Haitao
Li, Xiaoyan
Hu, Yi
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2021, 45 (05)
[2] Development and Validation of an Inflammatory Prognostic Index to Predict Outcomes in Advanced/Metastatic Urothelial Cancer Patients Receiving Immune Checkpoint Inhibitors
Mokbel, Sara
Baciarello, Giuilia
Lavaud, Pernelle
Omlin, Aurelius
Calabro, Fabio
Cathomas, Richard
Aeppli, Stefanie
Parent, Pauline
Giannatempo, Patrizia
Koster, Kira-Lee
Appel, Naara
Gonnet, Philippe
Angius, Gesuino
Tsantoulis, Petros
Arkenau, Hendrick-Tobias
Cattrini, Carlo
Messina, Carlo
Zeghondy, Jean
Morelli, Cristina
Loriot, Yohann
Formica, Vincenzo
Patrikidou, Anna
CANCERS, 2024, 16 (08)
[3] Development and Validation of a Prognostic Risk Model for Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors
Stukalin, Igor
Navani, Vishal
Gupta, Mehul
Ruan, Yibing
Boyne, Devon J.
O'Sullivan, Dylan E.
Meyers, Daniel E.
Goutam, Siddhartha
Sander, Michael
Ewanchuk, Benjamin W.
Brenner, Darren R.
Suo, Aleksi
Cheung, Winson Y.
Heng, Daniel Y. C.
Monzon, Jose G.
Cheng, Tina
ONCOLOGIST, 2023, 28 (09): : 812 - 822
[4] Baseline IPI (immune prognostic index) predicts survival in patients with advanced cervical cancer treated with immune checkpoint inhibitors (ICI)
Blanc-Durand, F.
Richardson, M.
Vuagnat, P.
Pautier, P.
Hollebecque, A.
Varga, A.
Massard, C.
Leary, A.
ANNALS OF ONCOLOGY, 2019, 30
[5] Prognostic nutritional index as a prognostic biomarker for gastrointestinal cancer patients treated with immune checkpoint inhibitors
Zhang, Lilong
Ma, Wangbin
Qiu, Zhendong
Kuang, Tianrui
Wang, Kunpeng
Hu, Baohong
Wang, Weixing
FRONTIERS IN IMMUNOLOGY, 2023, 14
[6] The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors
Meyers, Daniel E.
Stukalin, Igor
Vallerand, Isabelle A.
Lewinson, Ryan T.
Suo, Aleksi
Dean, Michelle
North, Scott
Pabani, Aliyah
Cheng, Tina
Heng, Daniel Y. C.
Bebb, D. Gwyn
Morris, Don G.
CANCERS, 2019, 11 (11)
[7] Development and Validation of a Prognostic Model for Patients with Advanced Lung Cancer Treated with the Immune Checkpoint Inhibitor Atezolizumab
Hopkins, Ashley M.
Kichenadasse, Ganessan
Garrett-Mayer, Elizabeth
Karapetis, Christos S.
Rowland, Andrew
Sorich, Michael J.
CLINICAL CANCER RESEARCH, 2020, 26 (13) : 3280 - 3286
[8] Impact of antibiotic use and other concomitant medications on the efficacy of immune checkpoint inhibitors in patients with advanced cancer
Iglesias-Santamaria, A.
CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22 (09): : 1481 - 1490
[9] Impact of antibiotic use and other concomitant medications on the efficacy of immune checkpoint inhibitors in patients with advanced cancer
A. Iglesias-Santamaría
Clinical and Translational Oncology, 2020, 22 : 1481 - 1490
[10] EFFECT OF CANCER STAGE ON ADVERSE KIDNEY OUTCOMES IN PATIENTS WITH ADVANCED MELANOMA TREATED WITH IMMUNE CHECKPOINT INHIBITORS
Wang, Qiyu
Strohbehn, Ian
Strohbehn, Samuel
Lee, Meghan
Seethapathy, Harish
Hanna, Paul
Fadden, Riley
Reynolds, Kerry
Sullivan, Ryan
Zhao, Sophia
Boland, Genevieve
Sise, Meghan
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 : I252 - I253

← 1 2 3 4 5 →